Endpoints | |
---|---|
MRI substudy | |
Primary efficacy endpoint | Absolute change in cardiac T2* from Baseline to each follow-up evaluation |
Secondary endpoints | •Proportion of patients who develop cardiac T2* value <20 msec at any time point •Proportion of patients who develop cardiac T2* value <10 msec at any time point •Change in liver iron concentration as determined by T2* from Baseline to each follow-up evaluation •Change in pancreatic T2* from Baseline to each follow-up period •Change in mean ferritin, transferrin saturation, liver function test, and thyroid function test values from Baseline to each follow-up evaluation •Change in blood glucose and glycosylated hemoglobin from Baseline to each follow-up evaluation |